A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kinnate Biopharma Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,300 shares of KNTE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,300
Previous 3,400 61.76%
Holding current value
$0
Previous $8,000 62.5%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.24 - $2.66 $450,638 - $535,133
-201,178 Reduced 48.38%
214,664 $571,000
Q4 2023

Feb 14, 2024

SELL
$1.07 - $2.5 $689,081 - $1.61 Million
-644,001 Reduced 60.76%
415,842 $985,000
Q3 2023

Nov 14, 2023

SELL
$1.38 - $3.31 $36,629 - $87,857
-26,543 Reduced 2.44%
1,059,843 $1.48 Million
Q2 2023

Aug 14, 2023

BUY
$2.33 - $6.84 $29,910 - $87,805
12,837 Added 1.2%
1,086,386 $3.29 Million
Q1 2023

May 15, 2023

SELL
$3.46 - $7.98 $103,194 - $238,003
-29,825 Reduced 2.7%
1,073,549 $6.71 Million
Q4 2022

Feb 14, 2023

BUY
$5.26 - $12.19 $37,203 - $86,219
7,073 Added 0.65%
1,103,374 $6.73 Million
Q3 2022

Nov 14, 2022

SELL
$9.86 - $15.76 $306,527 - $489,946
-31,088 Reduced 2.76%
1,096,301 $13.1 Million
Q2 2022

Aug 15, 2022

SELL
$7.43 - $13.0 $42,090 - $73,645
-5,665 Reduced 0.5%
1,127,389 $14.2 Million
Q1 2022

May 16, 2022

BUY
$7.73 - $17.99 $87,735 - $204,186
11,350 Added 1.01%
1,133,054 $12.8 Million
Q4 2021

Feb 14, 2022

SELL
$16.5 - $25.48 $537,388 - $829,858
-32,569 Reduced 2.82%
1,121,704 $19.9 Million
Q3 2021

Nov 15, 2021

SELL
$17.81 - $24.87 $2.61 Million - $3.65 Million
-146,614 Reduced 11.27%
1,154,273 $26.6 Million
Q2 2021

Aug 16, 2021

SELL
$22.19 - $31.55 $327,590 - $465,772
-14,763 Reduced 1.12%
1,300,887 $30.3 Million
Q1 2021

May 17, 2021

BUY
$26.99 - $40.0 $4,048 - $6,000
150 Added 0.01%
1,315,650 $41 Million
Q4 2020

Feb 16, 2021

BUY
$36.35 - $45.25 $47.8 Million - $59.5 Million
1,315,500 New
1,315,500 $52.3 Million

Others Institutions Holding KNTE

About Kinnate Biopharma Inc.


  • Ticker KNTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,145,600
  • Description
  • Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...
More about KNTE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.